HDB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HDB exhibits a stable financial health profile with a Piotroski F-Score of 5/9, though it lacks an Altman Z-Score as is typical for banking institutions. The current price of $25.71 is almost perfectly aligned with its growth-based intrinsic value of $26.1, suggesting the stock has reached a fundamental floor after a severe correction. While the company maintains a strong track record of earnings surprises and a 'Strong Buy' analyst consensus, these are offset by negative YoY revenue growth and a completely bearish technical trend (0/100). The valuation is further complicated by an exceptionally high Price-to-Book ratio of 10.61, which is aggressive for the regional banking sector.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
HDB vs JPM: Head-to-Head Comparison
This page compares HDFC Bank Limited (HDB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.